Scott R Solomon

Scott R Solomon

UNVERIFIED PROFILE

Are you Scott R Solomon?   Register this Author

Register author
Scott R Solomon

Scott R Solomon

Publications by authors named "Scott R Solomon"

Are you Scott R Solomon?   Register this Author

36Publications

960Reads

22Profile Views

Real-world outcomes of unselected elderly acute myeloid leukemia patients referred to a leukemia/hematopoietic cell transplant program.

Bone Marrow Transplant 2020 Jan 16;55(1):189-198. Epub 2019 Sep 16.

Leukemia/Blood and Marrow Transplant Program, Northside Hospital Cancer Institute, Atlanta, GA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0675-1DOI Listing
January 2020

Fludarabine and Total-Body Irradiation Conditioning before Ablative Haploidentical Transplantation: Long-Term Safety and Efficacy.

Biol Blood Marrow Transplant 2019 Nov 25;25(11):2211-2216. Epub 2019 Jun 25.

The Blood and Marrow Transplant Program at Northside Hospital, Atlanta, Georgia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.06.017DOI Listing
November 2019

Who Is a Better Donor for Recipients of Allogeneic Hematopoietic Cell Transplantation: A Young HLA-Mismatched Haploidentical Relative or an Older Fully HLA-Matched Sibling or Unrelated Donor?

Biol Blood Marrow Transplant 2019 Oct 4;25(10):2054-2060. Epub 2019 Jun 4.

Blood and Marrow Transplant Program at Northside Hospital, Atlanta, Georgia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.05.031DOI Listing
October 2019

Safety and efficacy of rituximab-based first line treatment of chronic GVHD.

Bone Marrow Transplant 2019 Aug 5;54(8):1218-1226. Epub 2018 Dec 5.

The Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41409-018-0399-7
Publisher Site
http://dx.doi.org/10.1038/s41409-018-0399-7DOI Listing
August 2019

The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation.

Biol Blood Marrow Transplant 2019 03 19;25(3):606-612. Epub 2018 Sep 19.

Blood and Marrow Transplant Program at Northside Hospital, Atlanta Georgia; Center for Clinical and Translational Sciences, University of Texas Health Science Center at Houston, Houston, Texas.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10838791183056
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2018.09.012DOI Listing
March 2019

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.

J Clin Oncol 2018 09 19;36(26):2684-2692. Epub 2018 Jul 19.

Jeffrey E. Lancet, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Geoffrey L. Uy, Washington University School of Medicine, St Louis, MO; Jorge E. Cortes, The University of Texas MD Anderson Cancer Center, Houston, TX; Laura F. Newell, Oregon Health & Science University, Portland, OR; Tara L. Lin, University of Kansas Medical Center, Kansas City, KS; Ellen K. Ritchie, Weill Cornell Medical College, New York; Jonathan E. Kolitz, Northwell Health System, Lake Success; Daniel H. Ryan, University of Rochester, Rochester, NY; Robert K. Stuart, Medical University of South Carolina, Charleston, SC; Stephen A. Strickland, Vanderbilt-Ingram Cancer Center, Nashville, TN; Donna Hogge, Leukemia/Bone Marrow Transplant Program of British Columbia, Vancouver, British Columbia, Canada; Scott R. Solomon, The Leukemia Program at Northside Hospital Cancer Center Institute, Atlanta, GA; Richard M. Stone, Dana-Farber Cancer Institute, Boston, MA; Dale L. Bixby, University of Michigan, Grass Lake, MI; Gary J. Schiller, University of California-Los Angeles, Los Angeles; Matthew J. Wieduwilt, University of California-San Diego, La Jolla; Kamalika Banerjee, Michael Chiarella, Arthur C. Louie, Jazz Pharmaceuticals, Palo Alto; Bruno C. Medeiros, Stanford University School of Medicine, Stanford, CA; and Antje Hoering, Cancer Research and Biostatistics, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.77.6112DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6127025PMC
September 2018

Long term survival among patients who are disease free at 1-year post allogeneic hematopoietic cell transplantation: a single center analysis of 389 consecutive patients.

Bone Marrow Transplant 2018 05 15;53(5):576-583. Epub 2018 Jan 15.

Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-017-0076-2DOI Listing
May 2018

Current Graft-versus-Host Disease-Free, Relapse-Free Survival: A Dynamic Endpoint to Better Define Efficacy after Allogenic Transplant.

Biol Blood Marrow Transplant 2017 Jul 5;23(7):1208-1214. Epub 2017 Apr 5.

The Blood and Marrow Transplant Program at Northside Hospital, Atlanta, Georgia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2017.02.022DOI Listing
July 2017

Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia.

Biol Blood Marrow Transplant 2016 10 21;22(10):1816-1822. Epub 2016 Jul 21.

The Blood and Marrow Transplant Program at Northside Hospital, Atlanta, Georgia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2016.07.010DOI Listing
October 2016

Haploidentical versus Matched Unrelated Donor Peripheral Blood Stem Cell Transplantation for Acute Myeloid Leukemia: Should Donor Type Matter Anymore?

Authors:
Scott R Solomon

Biol Blood Marrow Transplant 2016 09 22;22(9):1540-1542. Epub 2016 Jun 22.

Blood and Marrow Transplant Program, Northside Hospital, Atlanta, Georgia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2016.06.019DOI Listing
September 2016

Factors Predicting Graft-versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Hematopoietic Cell Transplantation: Multivariable Analysis from a Single Center.

Biol Blood Marrow Transplant 2016 08 14;22(8):1403-1409. Epub 2016 Apr 14.

Blood and Marrow Transplant Program at Northside Hospital, Atlanta, Georgia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2016.04.006DOI Listing
August 2016

Myeloablative Conditioning with PBSC Grafts for T Cell-Replete Haploidentical Donor Transplantation Using Posttransplant Cyclophosphamide.

Adv Hematol 2016 21;2016:9736564. Epub 2016 Jan 21.

Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA 30342, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2016/9736564DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4745340PMC
February 2016

Corticosteroid-Free Primary Treatment of Chronic Extensive Graft-versus-Host Disease Incorporating Rituximab.

Biol Blood Marrow Transplant 2015 Sep 16;21(9):1576-82. Epub 2015 May 16.

Blood and Marrow Transplant Program at Northside Hospital, Atlanta, Georgia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2015.04.023DOI Listing
September 2015

Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia.

J Clin Oncol 2015 Apr 2;33(11):1252-7. Epub 2015 Mar 2.

Richard M. Stone, Emanuele Mazzola, and Donna Neuberg, Dana-Farber Cancer Institute, Boston; Ante S. Lundberg, Antisoma, Cambridge, MA; Steven L. Allen, Hofstra North Shore-Long Island Jewish School of Medicine, Lake Success; Meir Wetzler, Roswell Park Cancer Institute, Buffalo; Martin S. Tallman, Memorial Sloan Kettering Cancer Center, New York, NY; Arnaud Pigneux, Hopital Haut-Leveque, Pessac, France; Robert K. Stuart, Medical University of South Carolina, Charleston, SC; David Rizzieri, Duke University Medical Center, Durham; Bayard Powell, Wake Forest University Comprehensive Cancer Center, Winston Salem, NC; Harry P. Erba, University of Michigan Health System, Ann Arbor, MI; Lloyd Damon, University of California San Francisco, San Francisco, CA; Jun-Ho Jang, Samsung Medical Center, Seoul, Korea; Krzysztof Warzocha, Institute of Hematology and Transfusiology, Warsaw, Poland; Támas Masszi, Szent Istvan and Szent Laszlo Corporate Hospital, Budapest; Miklos Egyed, Kaposi Mor County Teaching Hospital, Kasposvar, Hungary; Mikkael A. Sekeres, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Heinz-August Horst, Universitatsklinikum Schleswig-Holstein, Kiel, Germany; Dominik Selleslag, Algemeen Ziekenhuis Sint-Jan, Brugge, Belgium; Scott R. Solomon, Blood and Marrow Transplant Program and Northside Hospital, Atlanta, GA; and Parameswaran Venugopal, Rush University Medical Center, Chicago, IL.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2015/02/26/JCO.2014.57
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.57.0952
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.57.0952DOI Listing
April 2015

International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia.

J Clin Oncol 2014 Jun 19;32(18):1919-26. Epub 2014 May 19.

Gail J. Roboz, Weill Cornell Medical College and the New York Presbyterian Hospital; Todd Rosenblat, Columbia University Medical Center, New York, NY; Martha Arellano, Winship Cancer Institute at Emory University; Scott R. Solomon, The Blood and Marrow Transplant Group of Georgia, Atlanta, GA; Jessica K. Altman, Francis J. Giles, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Casey O'Connell, University of Southern California Norris Comprehensive Cancer Center and Hospital, Los Angeles, CA; Marco Gobbi, Azienda Ospedaliera Universitaria San Martino, University of Genoa, Genoa, Italy; Pau Montesinos, Hospital Universitario y Politécnico La Fé, Valencia, Spain; Arnaud Pigneux, Centre Hospitalier Universitaire de Bordeaux Hôpital Haut-Lévêque, Pessac; Norbert Vey, L'Institut Paoli-Calmettes, Marseilles, France; Robert Hills, Cardiff University School of Medicine, Cardiff, United Kingdom; Tove Flem Jacobsen, Athos Gianella-Borradori, Øivind Foss, and Sylvia Vetrhus, Clavis Pharma ASA, Oslo, Norway.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.52.8562DOI Listing
June 2014

Lineage-specific engraftment and outcomes after T-cell-depleted peripheral blood stem cell transplant with Flu/Cy/TBI conditioning.

Br J Haematol 2005 Sep;130(5):733-9

Stem Cell Allogeneic Transplantation Section, Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892-1202, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/j.1365-2141.2005.05665.x
Publisher Site
http://dx.doi.org/10.1111/j.1365-2141.2005.05665.xDOI Listing
September 2005

Improved outcome for peripheral blood stem cell transplantation for advanced primary myelodysplastic syndrome.

Biol Blood Marrow Transplant 2005 Aug;11(8):619-26

Stem Cell Allotransplantation Section, Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892-1202, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2005.05.004DOI Listing
August 2005